| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 1997;113:1-009
© 1997 Mosby, Inc.
CARDIAC AND PULMONARY REPLACEMENT |
Received for publication Sept. 12, 1995 revisions requested Oct. 31, 1995; revisions received Dec. 28, 1995 Accepted for publication Feb. 13, 1996 Address for reprints: Hiromi Wada, MD, Department of Thoracic Surgery, Chest Disease Research Institute, Kyoto University, Shogoin, Sakyo-ku, Kyoto 606, Japan.
Abstract
Human thioredoxin is a polypeptide with thiol groups, possessing reducing activity, which is proved to have the ability to reduce active oxygens. This study evaluated the effect of human thioredoxin on the ischemia-reperfusion lung injury and the roles of human thioredoxin on active oxygens by chemiluminescence examination. The left hilum of the lung of Japanese white rabbits was occluded for 110 minutes and then reperfused for 90 minutes. Ten, 30, 60, and 90 minutes after reperfusion the right hilum was occluded for 5 minutes and the pulmonary functions of the left lung were examined. The animals were divided into four groups, three ischemia groups and a sham group (without occlusion; n = 6). The ischemia groups received human thioredoxin, 60 mg/kg (n = 10), N-acetylcysteine, 150 mg/kg (n = 7), or saline solution (control, n = 10) during reperfusion. Three rabbits in the human thioredoxin group and the control group were used to measure active oxygens with a cypridina luciferin analog. An additional group of reperfused lungs (n = 3) that were given superoxide dismutase after 110 minutes of ischemia was established to identify chemiluminescence examination. Compared with the sham group, reperfusion after 110 minutes of ischemia produced a significant lung injury in the control group. Among the ischemia groups, the human thioredoxin group showed significantly higher arterial oxygen tension at 30, 60, and 90 minutes after reperfusion than the control group, although there was no significant difference between the N-acetylcysteine and control groups. Histologically, intraalveolar exudation, interstitial thickening, and cellular infiltration were seen in the control group, whereas in the thioredoxin group alveolar structure was well preserved. In the measurement of active oxygens the chemiluminescence in the human thioredoxin group was less than that in the control group and as little as that in the group administered superoxide dismutase. We concluded human thioredoxin attenuated ischemia-reperfusion injury by involving active oxygens in rabbit lungs.
This article has been cited by other articles:
|
|
 |
|
  T. E. Tipple, S. E. Welty, L. K. Rogers, T. N. Hansen, Y.-E. Choi, J. P. Kehrer, and C. V. Smith Thioredoxin-Related Mechanisms in Hyperoxic Lung Injury in Mice Am. J. Respir. Cell Mol. Biol., October 1, 2007; 37(4): 405 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Shamaei-Tousi, J. P. Halcox, and B. Henderson Stressing the obvious? Cell stress and cell stress proteins in cardiovascular disease Cardiovasc Res, April 1, 2007; 74(1): 19 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ohashi, A. Nishio, H. Nakamura, M. Kido, S. Ueno, N. Uza, S. Inoue, H. Kitamura, K. Kiriya, M. Asada, et al. Protective roles of redox-active protein thioredoxin-1 for severe acute pancreatitis Am J Physiol Gastrointest Liver Physiol, April 1, 2006; 290(4): G772 - G781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Billiet, C. Furman, G. Larigauderie, C. Copin, K. Brand, J.-C. Fruchart, and M. Rouis Extracellular Human Thioredoxin-1 Inhibits Lipopolysaccharide-induced Interleukin-1{beta} Expression in Human Monocyte-derived Macrophages J. Biol. Chem., December 2, 2005; 280(48): 40310 - 40318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tanito, A. Nishiyama, T. Tanaka, H. Masutani, H. Nakamura, J. Yodoi, and A. Ohira Change of Redox Status and Modulation by Thiol Replenishment in Retinal Photooxidative Damage Invest. Ophthalmol. Vis. Sci., July 1, 2002; 43(7): 2392 - 2400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tanito, H. Masutani, H. Nakamura, A. Ohira, and J. Yodoi Cytoprotective Effect of Thioredoxin against Retinal Photic Injury in Mice Invest. Ophthalmol. Vis. Sci., April 1, 2002; 43(4): 1162 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Nakamura, L. A. Herzenberg, J. Bai, S. Araya, N. Kondo, Y. Nishinaka, L. A. Herzenberg, and J. Yodoi Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis PNAS, December 6, 2001; (2001) 191498798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nakamura, S. C. De Rosa, J. Yodoi, A. Holmgren, P. Ghezzi, L. A. Herzenberg, and L. A. Herzenberg Chronic elevation of plasma thioredoxin: Inhibition of chemotaxis and curtailment of life expectancy in AIDS PNAS, February 27, 2001; 98(5): 2688 - 2693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Carr-White, M. Kon, T. W. Koh, S. Glennan, F. D. Ferdinand, A. C. De Souza, J. R. Pepper, D. J. Pennell, D. G. Gibson, and M. H. Yacoub Right Ventricular Function After Pulmonary Autograft Replacement of the Aortic Valve Circulation, November 9, 1999; 100(90002): II-36 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Carr-White, S. Glennan, S. Edwards, F. D. Ferdinand, A. C. Desouza, J. R. Pepper, and M. H. Yacoub Pulmonary Autograft Versus Aortic Homograft for Rereplacement of the Aortic Valve : Results From a Subset of a Prospective Randomized Trial Circulation, November 9, 1999; 100(90002): II-103 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nakamura, L. A. Herzenberg, J. Bai, S. Araya, N. Kondo, Y. Nishinaka, L. A. Herzenberg, and J. Yodoi Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis PNAS, December 18, 2001; 98(26): 15143 - 15148. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
